PubMedArquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery2026-11-12
Perioperative immunotherapy in resectable gastric adenocarcinoma: a critical review of current evidence.
Patino-Perez Valentina V, Castrillón-Arango Sarita S, Botello-Valencia Yensy Paola YP, Muñoz-Ruiz Edwin Oveimar EO et al.
Gastric cancer ranks fifth in global cancer incidence and fourth in mortality. In patients with gastric adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel, the FLOT regimen, constitutes the current therapeutic standard. Incorporating immune checkpoint inhibitors into perioperative schemes has emerged as a promising strategy, although its clinical and surgical impact requires critical appraisal in light of current evidence.
To critically analyze contemporary scientific evidence on incorporating perioperative immunotherapy into resectable gastric adenocarcinoma management, evaluating its impact on oncologic outcomes, perioperative safety, and its role within current therapeutic algorithms.
A critical narrative review through systematic searches in PubMed/MEDLINE, Embase, and Cochrane Library using relevant terms of the Medical Subject Headings (MeSH) thesaurus.
The MATTERHORN trial demonstrated that the addition of durvalumab to FLOT significantly improves event-free survival (hazard ratio 0.71; 95%CI 0.58-0.86; p<0.001) and overall survival (hazard ratio 0.78; 95%CI 0.63-0.96; p=0.021), with a pathological complete response rate of 19.2% versus 7.2%, without increased surgical morbidity or mortality. The KEYNOTE-585 trial demonstrated improved pathological complete response with pembrolizumab, without significant overall survival benefit. Microsatellite instability-high, human epidermal growth factor receptor 2, and programmed death ligand 1 biomarkers are key determinants in therapeutic selection. Perioperative immune-related adverse events require specific surveillance.
Adding durvalumab to FLOT establishes a new perioperative standard with level I evidence. Preoperative molecular characterization is key to decision-making. Integrating immunotherapy does not compromise the feasibility of gastrectomy with extended second-level lymphadenectomy, but requires specific expertise to manage immune-related toxicities. Durvalumab added to the fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen significantly improves event-free survival and overall survival, with pathological complete response, without increased surgical morbidity. The KEYNOTE-585 trial showed improved pathological complete response with pembrolizumab but failed to demonstrate overall survival benefit, confirming that immunotherapy efficacy is not uniform across agents or unselected populations. Preoperative molecular profiling of MSI-H, PD-L1, and HER2 status is now the central axis for individualized therapeutic decision-making in resectable gastric adenocarcinoma. Perioperative immunotherapy does not compromise the feasibility of gastrectomy with extended second-level lymphadenectomy but requires specific institutional expertise to manage immune-related adverse events.
Gastric cancer continues to represent a significant oncologic burden worldwide, ranking fifth in incidence and fourth in mortality. Its high lethality is related to the frequent diagnosis at locally advanced stages and its aggressive biological behavior, particularly in high-risk regions such as East Asia and Latin America. In this context, radical gastrectomy with extended second-level lymphadenectomy constitutes the cornerstone of curative-intent treatment, providing adequate locoregional control and precise staging. Incorporating multimodal strategies, such as perioperative chemotherapy, has demonstrated improved oncologic outcomes compared with surgery alone. The associated immunotherapy based on immune checkpoint inhibitors has emerged as a promising strategy.
The approval of durvalumab in combination with the fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen establishes a new perioperative standard with level I evidence, while the results of KEYNOTE-585 underscore that this benefit is neither uniform across agents nor applicable to unselected populations. Preoperative molecular characterization - particularly the determination of MSI-H, PD-L1, and HER2 - ceases to be a staging exercise to become the axis upon which the individual therapeutic strategy is constructed: it defines the systemic regimen, anticipates the probability of pathological complete response, and, in the MSI-H subgroup, opens the possibility of exploring - within the strict framework of research protocols - whether gastrectomy is necessary when treatment response is complete.